Nanosuspension: A new vehicle for the improvement of the delivery of drugs to the ocular surface. Application to amphotericin B

Nanomedicine: Nanotechnology, Biology, and Medicine

Volumn 7, Issue 2, 2011, Pages 242-247

  Das, Swarnali ^a   Suresh, Preeti K ^b  

^a Shri Vile Parle Kelavani Mandal's Narsee Monjee Institute of Management Studies   (India)

^b PT RAVISHANKAR SHUKLA UNIVERSITY   (India)

Author keywords

Amphotericin B; Eudragit RS 100; Nanosuspension; Ocular

Indexed keywords

AMPHOTERICIN B; ANTI-FUNGAL ACTIVITY; CATIONIC NANOPARTICLES; EUDRAGIT; EUDRAGIT RS 100; FUNGAL DISEASE; FUNGAL INFECTION; IN-VITRO; IN-VIVO EXPERIMENTS; INTRAOCULAR; MEAN SIZE; MICROBIAL ASSAY; MODEL COMPOUND; NANO-SUSPENSIONS; NANOSUSPENSION; OCULAR; RABBIT EYES; STABILITY STUDY;

DISEASE CONTROL; DISSOLUTION; DRUG DELIVERY; NANOPARTICLES; ZETA POTENTIAL;

FUNGI;

AMPHOTERICIN B; EUDRAGIT RS;

ANIMAL EXPERIMENT; ANTIFUNGAL ACTIVITY; ARTICLE; CONTROLLED STUDY; DRUG DELIVERY SYSTEM; DRUG FORMULATION; DRUG RELEASE; EYE; FUSARIUM SOLANI; INFRARED SPECTROSCOPY; MALE; MYCOSIS; NONHUMAN; PARTICLE SIZE; ZETA POTENTIAL;

ACRYLIC RESINS; AMPHOTERICIN B; ANIMALS; ANTIFUNGAL AGENTS; DRUG CARRIERS; EYE; EYE INFECTIONS, FUNGAL; MUCOUS MEMBRANE; NANOPARTICLES; PARTICLE SIZE; RABBITS; SUSPENSIONS;

ORYCTOLAGUS CUNICULUS;

EID: 79952768867     PISSN: 15499634     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.nano.2010.07.003     Document Type: Article

References (18)

1. Lee V.H.L. Precorneal, corneal and postcorneal factors. Ophthalmic drug delivery systems 1993, 59-81. Marcel Dekker, New York. A.K. Mitra (Ed.).
2. Lee V.H.L., Robinson J.R. Review: topical ocular drug delivery: recent developments and future challenges. J Ocul Pharmacol 1986, 2:67-108.
3. Pignatello R., Bucolo C., Spedalieri G., Maltese A., Puglisi G. Flurbiprofen-loaded acrylate polymer nanosuspensions for ophthalmic application. Biomaterials 2002, 23:3247-3255.
4. Pignatello R., Bucolo C., Ferrara P., Maltese A., Puleo A., Puglisi G. Eudragit RS100® nanosuspensions for the ophthalmic controlled delivery of ibuprofen. Eur J Pharm Sci 2002, 16:53-61.
5. Morand K., Bartoletti A.C., Bochot A., Barratt G., Brandely M.L., Chast F. Liposomal amphotericin B eye drops to treat fungal keratitis: physico-chemical and formulation stability. Int J Pharm 2007, 344:150-153.
6. Juliano R.L., Grant C., Barber K.R., Kalp M. Mechanism of the selective toxicity of amphoterictn B incorporated into liposomes. Mol Pharmacol 1987, 31:1-11.
7. Mehta L.B., Hopfer R., Mills K., Juhano R. Lipoaomal amphotericin B is toxic to fungal cells but not to mammalian cells. Biochim Biophys Acta 1984, 770:230-234.
8. Fessi H., Puisieux F., Devissaguet J.P., Ammoury N., Benita S. Nanocapsule formation by interfacial polymer deposition following solvent displacement. Int J Pharm 1989, 55:R1-4.
9. Garg S.C., Jain R.K. Antimicrobial efficacy of essential oil from Curcuma caesia. Ind J Microbiol 1988, 38:69-170.
10. Mc-Donald T.O., Shadduck J.A. Eye irritation. Advances in modern toxicology 1977, Vol. 4:139-191. Wiley, New York. F.M. Marzulli, H.I. Maibach (Eds.).
11. Rex JH, Alexander BD, Andes D, Arthington-Skaggs B, Brown SD, Chaturveli V, et al. Reference method for broth dilution antifungal susceptibility testing of filamentous fungi; approved standard-second edition. Document M38-A. Vol. 28, No. 16 2008, Clinical and Laboratory Standards Institute, Wayne, PA.
12. Sternling CV, Scriven LE Interfacial turbulence: hydrodynamic instability and the Marangoni effect. Am Inst Chem Eng J 1959, 5:514-523.
13. Berg J. Interfacial hydrodynamics: an overview. Can Metal Quan 1982, 21:121-136.
14. Wasan DT Interfacial turbulence: spontaneous emulsification and evaporative convention. Contributed discussion. Interface Convres. Polym. Coatings Proc 1967, 83-88. Elsevier, New York. P.A. Weiss (Ed.).
15. Budhian A., Siegel S.J., Winey K.I. Haloperidol loaded PLGA nanoparticles: systematic study of particle size and drug content. Int J Pharm 2007, 336:367-375.
16. Bodmeier R., Chen H. Preparation and characterization of microspheres containing the anti-inflammatory agents, indomethacin, ibuprofen, and ketoprofen. J Control Release 1989, 10:167-175.
17. Perumal D., Dangor C.M., Alcock R.S., Hurbans N., Moopanar K.R. Effect of formulation variables on in vitro drug release and micrometric properties of modified release ibuprofen microspheres. J Microencaps 1999, 16:475-487.
18. Espuelas M.S., Legrand P., Irache J.M., Gamazo C., Orecchioni A.M., Devissaguet J., et al. Poly (ε-caprolactone) nanospheres as an alternative way to reduce amphotericin B toxicity. Int J Pharm 1997, 158:19-27.